Endologix Treats First Patients Using FDA-Approved PTAB Procedure with Detour System

Endologix, a medical device company focused on the treatment of vascular disease, today announced its first patients have undergone percutaneous transmural arterial bypass (PTAB) using the Detour system since its FDA approval. The Detour system, along with the Torus Stent Graft were added to the company’s product portfolio following its April 2021 acquisition of PQ Bypass.

PTAB with the Detour system, according to the company, enables physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg. Detour is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200mm to 460mm in length with chronic total occlusions from 100mm to 425mm or diffuse stenosis >70% that are considered not optional patients for surgical or alternative endovascular treatments.

For the procedures, Endologix worked with Cleveland Clinic’s Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute and Salinas Valley Health Medical Center.

“We are delighted to be able to introduce PTAB using the DETOUR System into clinical use,” said Matt Thompson, MD, president, and CEO of Endologix, in a press release announcing the procedures. "The Detour system is a pivotal addition to our product portfolio, which now offers differentiated therapies for both abdominal aortic aneurysms and PAD. The successful introduction at these leading institutions underscores our commitment to continuing to innovate on behalf of patients. Broadening our therapeutic profile is a key achievement as we transform Endologix into a leading interventional vascular company.”